Clinical and biological effects of 5-Azacitidine five days/monthly schedule in symptomatic low-risk (IPSS: 0-1) myelodisplastic patient

This article has no abstract
Epistemonikos ID: cf5c64b33da25394f7219099dbefce38c9639592
First added on: Feb 28, 2025